Pharmaceutical company GlaxoSmithKline (GSK) and the University of Oxford have teamed up to further advance research and development breakthroughs in neurological diseases, including FTD, with their new five-year collaborative project.

The project, known as the Oxford-GSK Institute of Molecular and Computational Medicine, aims to improve the success and speed of the research and development of new medicines. The institute, which will be based at the university, will begin with targeting neurological diseases such as Alzheimer’s and Parkinson’s, and will have other research focused on FTD and amyotrophic lateral sclerosis (ALS).

Louise Richardson, Vice Chancellor of the University of Oxford, said in a press release that “the Institute will create a unique partnership with staff from the university’s medical school and GSK working side-by-side to research and develop treatments for some of the most difficult to treat diseases.”

According to the press release, the Institute will evaluate and integrate new approaches in genetics, proteomics — the large-scale study of proteins — and digital pathology to better understand detailed patterns of disease.

Read more about the Oxford-GSK Institute of Molecular and Computational Medicine here.